Cancer Research and Treatment

Erratum

ERRATUM: Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy Alone for Advanced Gastric Cancer with Krukenberg Tumor: Jang Ho Cho, Jae Yun Lim, Ah Ran Choi, Sung Min Choi, Jong Won Kim, Seung Ho Choi, Jae Yong Cho; Cancer Res Treat. 2018;50(1):302-302. Published online December 6, 2017; DOI: https://doi.org/10.4143/crt.2013.175.2; Corrects: Cancer Res Treat 2015;47(4):697

PDF PubReader ePub

6,534 View
210 Download
2 Web of Science

Original Articles

Overexpression of Endoplasmic Reticulum Oxidoreductin 1-α (ERO1L) Is Associated with Poor Prognosis of Gastric Cancer: So-Young Seol, Chul Kim, Jae Yun Lim, Sun Och Yoon, Soon Won Hong, Jong Won Kim, Seung Ho Choi, Jae Yong Cho; Cancer Res Treat. 2016;48(4):1196-1209. Published online February 26, 2016; DOI: https://doi.org/10.4143/crt.2015.189

Purpose
Gastric cancer is the second leading cause of cancer-related death worldwide. Although surgery is the standard curative treatment for gastric cancer, relapse occurs in a large number of patients, except in the case of early diagnosed gastric cancer. Following previous studies that identified endoplasmic reticulum oxidoreductin 1-α (ERO1L) as a potential marker for gastric cancer, we investigated the functional role of ERO1L in gastric cancer.
Materials and Methods
For validation of microarray data, the mRNA expression level of ERO1L was measured by quantitative real-time reverse transcription polymerase chain reaction in 56 independent stage III gastric cancer patients. Immunohistochemical staining was performed to examine the protein expression level of ERO1L in 231 gastric cancer patients. Correlation between gene expression and cancer prognosis was evaluated.
Results
Patients with high ERO1L expression had poorer survival than those with low expression (p < 0.01). Functional assays demonstrated that ERO1L knockdown inhibited cell proliferation, migration, invasion, and chemoresistance. In addition, involvement of inactivation of Akt and JNK signaling in molecular mechanisms of ERO1L inhibition was demonstrated.
Conclusion
High expression of ERO1L is associated with poor prognosis of patients with gastric cancer. These results indicate that ERO1L expression may be a clinically promising therapeutic target for prevention of gastric cancer.

Citations

Citations to this article as recorded by

Biological mechanisms and clinical significance of endoplasmic reticulum oxidoreductase 1 alpha (ERO1α) in human cancer
Peng Chen, Amit Sharma, Hans Weiher, Ingo G.H. Schmidt-Wolf
Journal of Experimental & Clinical Cancer Research.2024;[Epub] CrossRef
Cordycepin reprogramming lipid metabolism to block metastasis and EMT via ERO1A/mTOR/SREBP1 axis in cholangiocarcinoma
Xuebing Zhou, Yuan Li, Chunyu Yang, Dan Chen, Tong Wang, Tesi Liu, Wendi Yan, Zhaoxia Su, Bosen Peng, Xiangshan Ren
Life Sciences.2023; 327: 121698. CrossRef
ERO1α promotes the proliferation and inhibits apoptosis of colorectal cancer cells by regulating the PI3K/AKT pathway
Min Wu, Ruixue Li, Jianyan Qin, Ziyuan Wang, Jiasen Guo, Fenghong Lv, Guoqin Wang, Youguang Huang
Journal of Molecular Histology.2023; 54(6): 621. CrossRef
Identification of novel small molecule inhibitors for endoplasmic reticulum oxidoreductase 1α (ERO1α) enzyme: structure-based molecular docking and molecular dynamic simulation studies
Hussam Albassam, Chetan H. Mehta, Usha Y. Nayak
Journal of Biomolecular Structure and Dynamics.2022; 40(23): 13218. CrossRef
MicroRNA-218-5p affects lung adenocarcinoma progression through targeting endoplasmic reticulum oxidoreductase 1 alpha
Gang Chen, Qihao Wang, Kunyu Wang
Bioengineered.2022; 13(4): 10061. CrossRef
ERO1L promotes the proliferation and metastasis of lung adenocarcinoma via the Wnt2/β‐catenin signaling pathway
Jinbao Xie, Guoliang Liao, Zhi Feng, Bo Liu, Xu Li, Minglian Qiu
Molecular Carcinogenesis.2022; 61(10): 897. CrossRef
Current therapeutic options for gastric adenocarcinoma
C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
Saudi Journal of Biological Sciences.2021; 28(9): 5371. CrossRef
circ‑ACACA promotes proliferation, invasion, migration and glycolysis of cervical cancer cells by targeting the miR‑582‑5p/ERO1A signaling axis
Dandan Huang, Cuimei Li
Oncology Letters.2021;[Epub] CrossRef
Increased Progastrin-Releasing Peptide Expression is Associated with Progression in Gastric Cancer Patients
Li Li, Xiaodong Yin, Hai Meng, Juanyu Hu, Zhengqing Yu, Jianyong Xu
Yonsei Medical Journal.2020; 61(1): 15. CrossRef
Delineation of hypoxia-induced proteome shifts in osteosarcoma cells with different metastatic propensities
Zifeng Song, Martin C. Pearce, Yuan Jiang, Liping Yang, Cheri Goodall, Cristobal L. Miranda, Milan Milovancev, Shay Bracha, Siva K. Kolluri, Claudia S. Maier
Scientific Reports.2020;[Epub] CrossRef
Role of the ERO1-PDI interaction in oxidative protein folding and disease
Andrea G. Shergalis, Shuai Hu, Armand Bankhead, Nouri Neamati
Pharmacology & Therapeutics.2020; 210: 107525. CrossRef
Perineural Invasion and Postoperative Adjuvant Chemotherapy Efficacy in Patients With Gastric Cancer
Qing Tao, Wen Zhu, Xiaohui Zhao, Mei Li, Yongqian Shu, Deqiang Wang, Xiaoqin Li
Frontiers in Oncology.2020;[Epub] CrossRef
ERO1L promotes NSCLC development by modulating cell cycle‐related molecules
Xiujuan Shi, Jiawen Wu, Yi Liu, Yuxiong Jiang, Changjiang Zhi, Jue Li
Cell Biology International.2020; 44(12): 2473. CrossRef
ERO1L promotes IL6/sIL6R signaling and regulates MUC16 expression to promote CA125 secretion and the metastasis of lung cancer cells
Yuanyuan lei, Ruochuan Zang, Zhiliang Lu, Guochao Zhang, Jianbing Huang, Chengming Liu, Zhanyu Wang, Shuangshuang Mao, Yun Che, Xinfeng Wang, Sufei Zheng, Lingling Fang, Nan Sun, Jie He
Cell Death & Disease.2020;[Epub] CrossRef
Hypoxia and Reactive Oxygen Species as Modulators of Endoplasmic Reticulum and Golgi Homeostasis
Daniela Mennerich, Sakari Kellokumpu, Thomas Kietzmann
Antioxidants & Redox Signaling.2019; 30(1): 113. CrossRef
Endoplasmic reticulum proteostasis control and gastric cancer
Yu Wang, Kai Wang, Yang Jin, Xia Sheng
Cancer Letters.2019; 449: 263. CrossRef
Analysis of the characteristics and expression profiles of coding and noncoding RNAs of human dental pulp stem cells in hypoxic conditions
Ruitang Shi, Haoqing Yang, Xiao Lin, Yangyang Cao, Chen Zhang, Zhipeng Fan, Benxiang Hou
Stem Cell Research & Therapy.2019;[Epub] CrossRef
A2ML1and otitis media: novel variants, differential expression, and relevant pathways
Eric D. Larson, Jose Pedrito M. Magno, Matthew J. Steritz, Erasmo Gonzalo d.V. Llanes, Jonathan Cardwell, Melquiadesa Pedro, Tori Bootpetch Roberts, Elisabet Einarsdottir, Rose Anne Q. Rosanes, Christopher Greenlee, Rachel Ann P. Santos, Ayesha Yousaf, Sv
Human Mutation.2019;[Epub] CrossRef
ROS Generation and Antioxidant Defense Systems in Normal and Malignant Cells
Anastasiya V. Snezhkina, Anna V. Kudryavtseva, Olga L. Kardymon, Maria V. Savvateeva, Nataliya V. Melnikova, George S. Krasnov, Alexey A. Dmitriev
Oxidative Medicine and Cellular Longevity.2019; 2019: 1. CrossRef
Control of Protein Homeostasis in the Early Secretory Pathway: Current Status and Challenges
Daria Sicari, Aeid Igbaria, Eric Chevet
Cells.2019; 8(11): 1347. CrossRef
ERO1α promotes hypoxic tumor progression and is associated with poor prognosis in pancreatic cancer
Nikhil Gupta, Jung Eun Park, Wilford Tse, Jee Keem Low, Oi Lian Kon, Neil McCarthy, Siu Kwan Sze
Oncotarget.2019; 10(57): 5970. CrossRef
Polyamine Metabolism and Oxidative Protein Folding in the ER as ROS-Producing Systems Neglected in Virology
Olga A. Smirnova, Birke Bartosch, Natalia F. Zakirova, Sergey N. Kochetkov, Alexander V. Ivanov
International Journal of Molecular Sciences.2018; 19(4): 1219. CrossRef
Combined expression of protein disulfide isomerase and endoplasmic reticulum oxidoreductin 1‑α is a poor prognostic marker for non‑small cell lung cancer
Kyoung Kim, Ae An, Ho Park, Kyu Jang, Woo Moon, Myoung Kang, Yong Lee, Ja Ku, Myoung Chung
Oncology Letters.2018;[Epub] CrossRef
High expression of IRE1 in lung adenocarcinoma is associated with a lower rate of recurrence
Toshio Sakatani, Keita Maemura, Noriko Hiyama, Yosuke Amano, Kousuke Watanabe, Hidenori Kage, Masashi Fukayama, Jun Nakajima, Yutaka Yatomi, Takahide Nagase, Daiya Takai
Japanese Journal of Clinical Oncology.2017; 47(6): 543. CrossRef
Omics technologies in diagnostics of lung adenocarcinoma
S.E. Novikova, L.K. Kurbatov, M.G. Zavialova, V.G. Zgoda, A.I. Archakov
Biomeditsinskaya Khimiya.2017; 63(3): 181. CrossRef
Omics technologies in diagnosis of lung adenocarcinoma
S. E. Novikova, L. K. Kurbatov, M. G. Zavialova, V. G. Zgoda, A. I. Archakov
Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry.2017; 11(4): 309. CrossRef
Expression of ERO1L in gastric cancer and its association with patient prognosis
Bo Zhou, Gongping Wang, Shegan Gao, Ye Chen, Canhui Jin, Zengfang Wang, Yantong Yang, Zhikun Ma, Wei Zhang, Xiaoshan Feng
Experimental and Therapeutic Medicine.2017; 14(3): 2298. CrossRef
Integrated expression profiles analysis reveals novel predictive biomarker in pancreatic ductal adenocarcinoma
Hongzhe Li, Xinjing Wang, Yuan Fang, Zhen Huo, Xiongxiong Lu, Xi Zhan, Xiaxin Deng, Chenghong Peng, Baiyong Shen
Oncotarget.2017; 8(32): 52571. CrossRef

13,053 View
218 Download
28 Web of Science
28 Crossref

Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy Alone for Advanced Gastric Cancer with Krukenberg Tumor: Jang Ho Cho, Jae Yun Lim, Ah Ran Choi, Sung Min Choi, Jong Won Kim, Seung Ho Choi, Jae Yong Cho; Cancer Res Treat. 2015;47(4):697-705. Published online November 27, 2014; DOI: https://doi.org/10.4143/crt.2013.175; Correction in: Cancer Res Treat 2018;50(1):302

Abstract PDF PubReader ePub

Purpose
This study was conducted to validate the survival benefit of metastasectomy plus chemotherapy over chemotherapy alone for treatment of Krukenberg tumors from gastric cancer and to identify prognostic factors for survival. Materials and Methods Clinical data from 216 patients with Krukenberg tumors from gastric cancer were collected. Patients were divided into two arms according to treatment modality: arm A, metastasectomy plus chemotherapy and arm B, chemotherapy alone. Results Overall survival (OS) was significantly increased in arm A relative to arm B for patients initially diagnosed with stage IV gastric cancer (18.0 months vs. 8.0 months; p < 0.001) and those with recurrent Krukenberg tumors (19.0 months vs. 9.0 months; p=0.002), respectively. Metastasectomy (hazard ratio [HR], 0.458; 95% confidence interval [CI], 0.287 to 0.732; p=0.001), signet-ring cell pathology (HR, 1.583; 95% CI, 1.057 to 2.371; p=0.026), and peritoneal carcinomatosis (HR, 3.081; 95% CI, 1.610 to 5.895; p=0.001) were significant prognostic factors for survival. Conclusion Metastasectomy plus chemotherapy offers superior OS when compared to palliative chemotherapy alone in gastric cancer with Krukenberg tumor. Prolonged survival applies to all patients, regardless of gastric cancer stage. Metastasectomy, signet-ring cell pathology, and peritoneal carcinomatosis were prognostic factors for survival. Future prospective randomized trials are needed to confirm the optimal treatment strategy for Krukenberg tumors from gastric cancer.

Citations

Citations to this article as recorded by

Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline)
In-Ho Kim, Seung Joo Kang, Wonyoung Choi, An Na Seo, Bang Wool Eom, Beodeul Kang, Bum Jun Kim, Byung-Hoon Min, Chung Hyun Tae, Chang In Choi, Choong-kun Lee, Ho Jung An, Hwa Kyung Byun, Hyeon-Su Im, Hyung-Don Kim, Jang Ho Cho, Kyoungjune Pak, Jae-Joon Kim
Journal of Gastric Cancer.2025; 25(1): 5. CrossRef
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
Feng‐Hua Wang, Xiao‐Tian Zhang, Lei Tang, Qi Wu, Mu‐Yan Cai, Yuan‐Fang Li, Xiu‐Juan Qu, Hong Qiu, Yu‐Jing Zhang, Jie‐Er Ying, Jun Zhang, Ling‐Yu Sun, Rong‐Bo Lin, Chang Wang, Hao Liu, Miao‐Zhen Qiu, Wen‐Long Guan, Sheng‐Xiang Rao, Jia‐Fu Ji, Yan Xin, Wei‐
Cancer Communications.2024; 44(1): 127. CrossRef
Oligometastasis of Gastric Cancer: A Review
Itaru Yasufuku, Hiroshi Tsuchiya, Seito Fujibayashi, Naoki Okumura, Yuki Sengoku, Masahiro Fukada, Ryuichi Asai, Yuta Sato, Jesse Yu Tajima, Shigeru Kiyama, Takazumi Kato, Yoshihiro Tanaka, Katsutoshi Murase, Nobuhisa Matsuhashi
Cancers.2024; 16(3): 673. CrossRef
Colorectal Origin: A Marker of Favorable Outcome in Krukenberg Tumor? Results from Clinical and Prognostic Analysis
Purnima Thakur, Mukesh Sharma, Ashish Chauhan, Kapil M. Pal, Shabnam Thakur, Manish Gupta, Shilpa Kaushal
South Asian Journal of Cancer.2024; 13(02): 099. CrossRef
Surgical resection and neoadjuvant therapy in patients with gastric cancer and ovarian metastasis: A real-world study
Hui-Ping Yan, Hong-Rui Lu, Yu-Xia Zhang, Liu Yang, Zhe-Ling Chen
World Journal of Gastrointestinal Surgery.2024; 16(8): 2426. CrossRef
MRI characteristics of ovarian metastasis: differentiation from stomach and colorectal cancer
Yukiko Takai, Hiroki Kato, Masaya Kawaguchi, Kazuhiro Kobayashi, Kyoko Kikuno, Tatsuro Furui, Masanori Isobe, Yoshifumi Noda, Fuminori Hyodo, Masayuki Matsuo
Japanese Journal of Radiology.2024;[Epub] CrossRef
Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach
Tae-Han Kim, In-Ho Kim, Seung Joo Kang, Miyoung Choi, Baek-Hui Kim, Bang Wool Eom, Bum Jun Kim, Byung-Hoon Min, Chang In Choi, Cheol Min Shin, Chung Hyun Tae, Chung sik Gong, Dong Jin Kim, Arthur Eung-Hyuck Cho, Eun Jeong Gong, Geum Jong Song, Hyeon-Su Im
Journal of Gastric Cancer.2023; 23(1): 3. CrossRef
Efficacy of chemotherapy combined with surgical resection for gastric cancer with synchronous ovarian metastasis: A propensity score matching analysis
Jingquan Fang, Xingmao Huang, Xiangliu Chen, Qi Xu, Tengjiao Chai, Ling Huang, Han Chen, Hang Chen, Zeyao Ye, Yian Du, Pengfei Yu
Cancer Medicine.2023; 12(16): 17126. CrossRef
Clinical Features of Gastric Signet Ring Cell Cancer: Results from a Systematic Review and Meta-Analysis
Mariagiulia Dal Cero, Maria Bencivenga, Drolaiz H. W. Liu, Michele Sacco, Mariella Alloggio, Kelly G. P. Kerckhoffs, Federica Filippini, Luca Saragoni, Mar Iglesias, Anna Tomezzoli, Fátima Carneiro, Heike I. Grabsch, Giuseppe Verlato, Lorena Torroni, Guil
Cancers.2023; 15(21): 5191. CrossRef
Frequency and therapeutic strategy for patients with ovarian metastasis from gastric cancer
Tsutomu Namikawa, Akira Marui, Keiichiro Yokota, Yasuhiro Kawanishi, Masaya Munekage, Sunao Uemura, Hiromichi Maeda, Hiroyuki Kitagawa, Michiya Kobayashi, Kazuhiro Hanazaki
Langenbeck's Archives of Surgery.2022; 407(6): 2301. CrossRef
Clinics and pathology of Krukenberg tumor: a systematic review and meta-analysis
Ruggero LIONETTI, Marcello DE LUCA, Antonio RAFFONE, Antonio TRAVAGLINO, Alberto COPPELLOTTI, Roberto PELTRINI, Umberto BRACALE, Michele D’AMBRA, Luigi INSABATO, Fulvio ZULLO, Maria D’ARMIENTO, Francesco CORCIONE
Minerva Obstetrics and Gynecology.2022;[Epub] CrossRef
Seventeen-year Survival of a Case of Advanced Gastric Cancer with Krukenberg Tumor Treated by Oophorectomies, Subsequent Gastrectomy, and Chemotherapy
Yoshiro NISHIWAKI, Hideto OCHIAI, Toshikazu KANAI, Hiroaki TAMURA, Tadataka HAYASHI, Shinichiro MIYAZAKI, Shinichi HASEGAWA, Takeshi BABA
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2022; 83(4): 675. CrossRef
Gastric linitis plastica due to signet-ring cell carcinoma with Krukenberg tumors diagnosed by endoscopic ultrasound-guided fine-needle aspiration
Takeshi Okamoto, Hidekazu Suzuki, Katsuyuki Fukuda
Clinical Journal of Gastroenterology.2021; 14(4): 994. CrossRef
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
Feng‐Hua Wang, Xiao‐Tian Zhang, Yuan‐Fang Li, Lei Tang, Xiu‐Juan Qu, Jie‐Er Ying, Jun Zhang, Ling‐Yu Sun, Rong‐Bo Lin, Hong Qiu, Chang Wang, Miao‐Zhen Qiu, Mu‐Yan Cai, Qi Wu, Hao Liu, Wen‐Long Guan, Ai‐Ping Zhou, Yu‐Jing Zhang, Tian‐Shu Liu, Feng Bi, Xian
Cancer Communications.2021; 41(8): 747. CrossRef
Is Routine Gastroscopy/Colonoscopy Reasonable in Patients With Suspected Ovarian Cancer: A Retrospective Study
Guochen Liu, Junping Yan, Shanshan Long, Zhimin Liu, Haifeng Gu, Hua Tu, Jundong Li
Frontiers in Oncology.2021;[Epub] CrossRef
Surgical management of oligometastatic disease in gastric cancer
Peng Jin, Xiaoyan Ji, Yantao Tian
Clinics and Research in Hepatology and Gastroenterology.2020; 44(5): 638. CrossRef
The role of surgical resection before palliative chemotherapy in advanced gastric cancer
Yong Won Choi, Mi Sun Ahn, Geum Sook Jeong, Hyun Woo Lee, Seong Hyun Jeong, Seok Yun Kang, Joon Seong Park, Jin-Hyuk Choi, Sang-Yong Son, Hoon Hur, Sang-Uk Han, Seung Soo Sheen
Scientific Reports.2019;[Epub] CrossRef
The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer
Feng‐Hua Wang, Lin Shen, Jin Li, Zhi‐Wei Zhou, Han Liang, Xiao‐Tian Zhang, Lei Tang, Yan Xin, Jing Jin, Yu‐Jing Zhang, Xiang‐Lin Yuan, Tian‐Shu Liu, Guo‐Xin Li, Qi Wu, Hui‐Mian Xu, Jia‐Fu Ji, Yuan‐Fang Li, Xin Wang, Shan Yu, Hao Liu, Wen‐Long Guan, Rui‐Hu
Cancer Communications.2019; 39(1): 1. CrossRef
Treatments and overall survival in patients with Krukenberg tumor
Ruggero Lionetti, Marcello De Luca, Antonio Travaglino, Antonio Raffone, Luigi Insabato, Gabriele Saccone, Massimo Mascolo, Maria D’armiento, Fulvio Zullo, Francesco Corcione
Archives of Gynecology and Obstetrics.2019; 300(1): 15. CrossRef
Effects of metastasectomy and other factors on survival of patients with ovarian metastases from gastric cancer: a systematic review and meta‐analysis
Chao Zhang, Wenbin Hou, Jinyu Huang, Songcheng Yin, Pengliang Wang, Zhe Zhang, Yuen Tan, Huimian Xu
Journal of Cellular Biochemistry.2019; 120(9): 14486. CrossRef
Multi-Modality Treatment for Patients With Metastatic Gastric Cancer: A Real-World Study in China
Lin Zhao, Jiarui Li, Chunmei Bai, Yongdu Nie, Guole Lin
Frontiers in Oncology.2019;[Epub] CrossRef
Prognostic factors in Krukenberg tumor
Ruggero Lionetti, Marcello De Luca, Antonio Travaglino, Antonio Raffone, Gabriele Saccone, Antonietta Di Cicco, Luigi Insabato, Massimo Mascolo, Maria D’Armiento, Fulvio Zullo, Francesco Corcione
Archives of Gynecology and Obstetrics.2019; 300(5): 1155. CrossRef
Palliative surgery for Krukenberg tumors – 12-year experience and review of the literature
Isaac Seow-En, Gwen Hwarng, Grace Hwei Ching Tan, Leonard Ming Li Ho, Melissa Ching Ching Teo
World Journal of Clinical Oncology.2018; 9(1): 13. CrossRef
Pressurized intraperitoneal aerosol chemotheprapy after misdiagnosed gastric cancer: Case report and review of the literature
Maciej Nowacki, Dariusz Grzanka, Wojciech Zegarski
World Journal of Gastroenterology.2018; 24(19): 2130. CrossRef
Is a Surgical Approach Justified in Metachronous Krukenberg Tumor from Gastric Cancer? A Systematic Review
Paolo Aurello, Giammauro Berardi, Laura Antolino, Giulio Antonelli, Alessia Rampini, Giovanni Moschetta, Giovanni Ramacciato
Oncology Research and Treatment.2018; 41(10): 644. CrossRef
An Unusual Cause of Acute Perforation
Najib Nassani, Liliane Deeb, Sherif Andrawes
Gastroenterology.2017; 152(5): 956. CrossRef
Krukenberg tumors: Seed, route and soil
Annamaria Agnes, Alberto Biondi, Riccardo Ricci, Valerio Gallotta, Domenico D'Ugo, Roberto Persiani
Surgical Oncology.2017; 26(4): 438. CrossRef
Comparison of a Panel of Biomarkers Between Gastric Primary Cancer and the Paired Krukenberg Tumor
Bo Wang, Ke Sun, Yinying Zou
Applied Immunohistochemistry & Molecular Morphology.2017; 25(9): 639. CrossRef
Treatment strategy and prognostic factors for Krukenberg tumors of gastric origin: report of a 10-year single-center experience from China
Pengfei Yu, Ling Huang, Guoping Cheng, Litao Yang, Gaiguo Dai, Jieer Ying, Yian Du
Oncotarget.2017; 8(47): 82558. CrossRef
Surgical treatment of gastric carcinoma with ovarian metastases
Tomasz Olesinski
Current Issues in Pharmacy and Medical Sciences.2017; 30(4): 195. CrossRef
Krukenberg Tumors of Gastric Origin: The Rationale of Surgical Resection and Perioperative Treatments in a Multicenter Western Experience
Fausto Rosa, Daniele Marrelli, Paolo Morgagni, Chiara Cipollari, Giovanni Vittimberga, Massimo Framarini, Luca Cozzaglio, Corrado Pedrazzani, Stefano Berardi, Gian Luca Baiocchi, Franco Roviello, Nazario Portolani, Giovanni de Manzoni, Guido Costamagna, G
World Journal of Surgery.2016; 40(4): 921. CrossRef

21,375 View
393 Download
35 Web of Science
31 Crossref

Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer: Ji Soo Park, Jae Yun Lim, Seung Kyo Park, Min Kyung Kim, Hee Sung Ko, Sun Och Yoon, Jong Won Kim, Seung Ho Choi, Jae Yong Cho; Cancer Res Treat. 2011;43(4):236-243. Published online December 27, 2011; DOI: https://doi.org/10.4143/crt.2011.43.4.236

Abstract PDF PubReader ePub

PURPOSE
The aims of this study are to find out whether the sequence of chemotherapeutic regimens including second- and third-line taxane and irinotecan influences the survival of patients with unresectable gastric carcinoma and to identify clinical characteristics of patients with improved response.
MATERIALS AND METHODS
Fifty gastric carcinoma patients who were treated by third-line sequential chemotherapy between November 2004 and July 2010 were enrolled in this study. Their overall survival (OS) and time to progression (TTP) were set up as primary and secondary end points. For the sequence of chemotherapy regimen, two arms were used. Arm A was defined as 5-fluorouracil (5-FU)+cisplatin (FP) or folinic acid, 5-FU and oxaliplati (FOLFOX), followed by folinic acid, 5-FU and irinotecan (FOLFIRI), and paclitaxel or docetaxel plus 5-FU, with or without epirubicin. Arm B was defined as FP or FOLFOX, followed by paclitaxel or docetaxel plus 5-FU, and FOLFIRI.
RESULTS
The median OS of all patients was 16.0 months (95% confidence interval, 13.6 to 18.3 months), which is longer than historical control of patients who did not receive third-line chemotherapy. The sequence of second and third-line regimen, including irinotecan and taxane, did not present significant difference in OS or TTP after failure of 5-FU with platinum chemotherapy. In survival analysis of patients' clinicopathologic characteristics, poor prognosis was shown in patients with poorly differentiated histologic features, elevated serum carcinoembryonic level, and shorter TTP of first line chemotherapy.
CONCLUSION
It is possible for patients to respond differently to chemotherapy due to differences in clinical features and underlying gene expression profiles. Development of individualized chemotherapy regimens based on gene expression profiles is warranted.

Citations

Citations to this article as recorded by

Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
Daniel V.T. Catenacci, Stephanie Moya, Samantha Lomnicki, Leah M. Chase, Bryan F. Peterson, Natalie Reizine, Lindsay Alpert, Namrata Setia, Shu-Yuan Xiao, John Hart, Uzma D. Siddiqui, D. Kyle Hogarth, Oliver S. Eng, Kiran Turaga, Kevin Roggin, Mitchell C.
Cancer Discovery.2021; 11(2): 308. CrossRef
Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer
Minkyu Jung, Kyu Hyun Park, Hyun Myong Kim, Tae Soo Kim, Xianglan Zhang, Sun-Mi Park, Seung-Hoon Beom, Hyo Song Kim, Jae-Ho Cheong, Hyun Cheol Chung, John Soong, Shu-chuan Lin, Sun Young Rha
Gastric Cancer.2019; 22(6): 1153. CrossRef
Advanced gastric cancer: is there an optimal chemotherapy regimen?
Kalliopi Andrikou, Massimiliano Salati, Annalisa Fontana, Andrea Spallanzani, Stefania Pipitone, Fabio Gelsomino, Monica Barbolini, Stefano Cascinu
Expert Review of Quality of Life in Cancer Care.2017; 2(2): 123. CrossRef
Third-line chemotherapy in advanced gastric cancer
Yu Zheng, Xu-Qing Zhu, Xiao-Gang Ren
Medicine.2017; 96(24): e6884. CrossRef
Melatonin pre-treatment mitigates SHSY-5Y cells against oxaliplatin induced mitochondrial stress and apoptotic cell death
Mohammad Waseem, Upasana Sahu, Mohd. Salman, Arnab Choudhury, Sudeshna Kar, Heena Tabassum, Suhel Parvez, Saeid Ghavami
PLOS ONE.2017; 12(7): e0180953. CrossRef
Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy
Valentina Fanotto, Mario Uccello, Irene Pecora, Lorenza Rimassa, Francesco Leone, Gerardo Rosati, Daniele Santini, Riccardo Giampieri, Samantha Di Donato, Gianluca Tomasello, Nicola Silvestris, Filippo Pietrantonio, Francesca Battaglin, Antonio Avallone,
The Oncologist.2017; 22(12): 1463. CrossRef
Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients
Lihong Huang, Yongyue Wei, Sipeng Shen, Qianwen Shi, Jianling Bai, Jin Li, Shukui Qin, Hao Yu, Feng Chen
Oncotarget.2017; 8(17): 29346. CrossRef
Apatinib for the treatment of gastric cancer
Giandomenico Roviello, Andrea Ravelli, Anna Ida Fiaschi, Maria Rosa Cappelletti, Angela Gobbi, Chiara Senti, Laura Zanotti, Karol Polom, Andrew R. Reynolds, Stephen B. Fox, Daniele Generali
Expert Review of Gastroenterology & Hepatology.2016; : 1. CrossRef
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Jin Li, Shukui Qin, Jianming Xu, Jianping Xiong, Changping Wu, Yuxian Bai, Wei Liu, Jiandong Tong, Yunpeng Liu, Ruihua Xu, Zhehai Wang, Qiong Wang, Xuenong Ouyang, Yan Yang, Yi Ba, Jun Liang, Xiaoyan Lin, Deyun Luo, Rongsheng Zheng, Xin Wang, Guoping Sun,
Journal of Clinical Oncology.2016; 34(13): 1448. CrossRef
Efficacy and Safety of FOLFIRI as Second-line Chemotherapy in Advanced Gastric Cancer
Sung Chul Park, Hoon Jai Chun
The Korean Journal of Gastroenterology.2015; 66(1): 1. CrossRef
Efficacy and Safety of FOLFIRI after Failure of FOLFOX-4 in Advanced Gastric Cancer
Hye Jung Kwon, Moo In Park, Seun Ja Park, Won Moon, Sung Eun Kim, Hae Won Lee, Youn Jung Choi, Jae Hyun Kim
The Korean Journal of Gastroenterology.2015; 66(1): 10. CrossRef
Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy
Vinod Vijay Subhash, Mei Shi Yeo, Woei Loon Tan, Wei Peng Yong
Journal of Immunology Research.2015; 2015: 1. CrossRef
Impact of the availability of active cytotoxic agents on the survival of patients with advanced gastric cancer
BYUNG HA CHO, HYE SOOK HAN, JIHYUN KWON, JOUNG-HO HAN, SOON MAN YOON, DAE HOON KIM, HYO YUNG YUN, KI HYEONG LEE, SEI JIN YOUN, SEUNG TAIK KIM
Oncology Letters.2015; 10(4): 2481. CrossRef
Design of precise third-line therapy for gastric cancer: target or chemotherpy?
Jae Yong Cho
The Korean Journal of Internal Medicine.2013; 28(3): 297. CrossRef
Sequential Chemotherapies for Advanced Gastric Cancer: A Retrospective Analysis of 111 Patients
Christoph Elsing, Christina Herrmann, Carla Verena Hannig, Wolfgang Stremmel, Dirk Jäger, Thomas Herrmann
Oncology.2013; 85(5): 262. CrossRef

13,539 View
68 Download
15 Crossref

Suppression of Peritoneal Metastases by Expression of Murine Endostatin cDNA: Seung Ho Choi, Jae Hoon Lee, Sung Hee Hong, Woo Jin Hyung, Sung Hoon Noh, Hyun Cheol Chung, Jae Kyung Roh, Jin Sik Min; Cancer Res Treat. 2002;34(4):302-307. Published online August 31, 2002; DOI: https://doi.org/10.4143/crt.2002.34.4.302

Abstract PDF

Peritoneal seeding is one of problems to be solved in gastrointestinal and ovarian cancers. Angiogenesis is the critical step for a dormancy tumor cluster to be an overt metastatic nodule. However, whether an anti-angiogenesis strategy is effective in the control of peritoneal metastases is still obscure. In this study, we evaluated whether endostatin, an endogenous angiogenesis inhibitor, suppresses peritoneal metastases.
MATERIALS AND METHODS
We transduced a human gastric cancer cell line, AGS and a murine renal cancer cell line, Renca, with the plasmid pEndoSTHB, which encodes a secretable form of murine endostatin. Endostatin expression was tested with western blotting, and the biological activity of the secreted endostatin was confirmed with in vitro endothelial cell growth inhibition. In the animal experiments, stable transfectants were injected intraperitoneally.
RESULTS
We demonstrated secretion of endostatin from two cell lines transduced with the plasmid pEndoSTHB. Conditioned media secreted from pEndoSTSB-transduced mammalian cells were shown to potently inhibit endothelial cell growth in vitro. We selected stable transfectants with similar in vitro growth rates of their parental cell lines. Significant tumor growth inhibition was observed in the endostatin-expressing Renca cells intraperitoneal injection group at days of 28, compared to the null transfectants intraperitoneal injection control group.
CONCLUSION
These results support that peritoneal seeding is angiogenesis-dependant and an anti-angiogenesis strategy is a good way to control peritoneal metastases.

Citations

Citations to this article as recorded by

The kringle domain of tissue-type plasminogen activator inhibits in vivo tumor growth
Byoung-Shik Shim, Byoung-Hak Kang, Yong-Kil Hong, Hyun-Kyung Kim, Il-Ha Lee, Soo-Young Lee, Young-Joon Lee, Suk-Keun Lee, Young Ae Joe
Biochemical and Biophysical Research Communications.2005; 327(4): 1155. CrossRef

4,190 View
22 Download
1 Crossref

Interaction between Genetic Polymorphisms of CYP2E1 & NAT1 and Smoking in Lung Cancer Development (Preliminary report): Kyoung Mu Lee, Seung Joon Lee, Sue Kyung Park, Sang Yun Lee, Hyung June Im, Ki Jung Yoon, In Mi Choi, Young Ju Lee, Soo Ung Kim, Hwang Choi, Seung Ho Choi, Young Whan Kim, Soo Han Cho, Daehee Kang; J Korean Cancer Assoc. 2001;33(1):41-48.

Abstract PDF: PURPOSE
The interactive effects of genetic polymorphisms of cytochrome P4502E1 (CYP2E1) & N-acetyltransferase 1 (NAT1) and smoking on lung cancer development were evaluated in hospital based case-control study.
MATERIALS AND METHODS
Male lung cancer patients (N= 157) and the male patients with no present or previous history of systemic illnesses who visited the urology department (N=138) were recruited (1998-1999). CYP2E1 & NAT1 genotypes were determined by PCR-RFLP method using RsaI and MboII digestion, respectively.
RESULTS
CYP2E1 c2 or NAT1 *10 allele did not increased the risk of lung cancer. Heavy smokers (35CONCLUSION
These results suggest the gene-environment interaction between genetic polymorphisms of CYP2E1 & NAT1 and smoking in lung cancer development.

3,547 View
25 Download

Gastric carcinoid tumor: Wan Soo Kim, Seung Ho Choi, Sung Hoon Noh, Jin Sik Min, Ho Geun Kim, Won Ho Kim; J Korean Cancer Assoc. 1991;23(3):596-605.

Abstract PDF: No abstract available.

2,580 View
13 Download

Remnant stomach cancer: Sung Hoon Noh, Dong Sup Yoon, Seung Ho Choi, Jin Sik Min, Jae Kyung Roh, Byung Soo Kim; J Korean Cancer Assoc. 1991;23(3):578-585.

Abstract PDF: No abstract available.

2,511 View
17 Download

Analysis of High Risk Factors for Lymph Node Metastasis in Early Gastric Cancer: Sung Hoon Noh, Wan Soo Kim, Ki Hyeok Lah, Yong Il Kim, Seung Ho Choi, Coong Bai Kim, Jin Sik Min, Kyung Shik Lee; J Korean Cancer Assoc. 1996;28(1):27-35.

Abstract PDF: The prognosis of early gastric cancer (EGC) is generally excellent, and the proportion of EGC cases to advanced gastric cancer cases is steadily increasing nowadays. The presence or absence of lymph node metastasis in EGC is important prognostic factor, in other words, the survival rate or recurrence rate of node negative EGC is known to be much better than that of node positive ones. Retrospective analysis was performed for 682 EGC cases which underwent more than D2 resection in Yonsei medical center between 1986 Jan. to 1993 Dec, in order to investigate the clinicopathological factors to predict the possibility of lymph node metastasis. In this study, several factors such as age, sex, tumor location, tumor size, multiplicity, depth of invasion, macroscopic and histologic type were evaluated to determine the significance. In the analysis of these eight factors, sex, tumor size, depth of invasion and macroscopic type were statistically correlated with lymph node metastasis. We consider these factors to be possible high risk factors for lymph node metastasis in early gastric cancer.

3,667 View
29 Download

Effect of Preoperative Transcatheter Arterial Chemoembolization on Recurrence Rate and Survival After Curative Resection in Patients with Hepatocellular Carcinoma: Dong Sup Yoon, Seung Ho Choi, Ki Whang Kim, Hoon Sang Chi, Byong Ro Kim; J Korean Cancer Assoc. 1996;28(4):726-733.

Abstract PDF: In order to evaluate the effect of preoperative transcatheter arterial chemoembolization on recurrence rate and survival after curative resection in patients with hepatocellular carcinoma, a retrospective clinical study of 57 patients underwent curative resection was performed. Fifty seven patients with hepatocellular carcinoma, underwent curative liver resection at Yongdong Severance Hospital from June 1985 to June 1995, were divided into two different treatment groups. Of the 57 patients, 25 patients(Group I) had received preoperative transcatheter arterial chemoembolization and 32(Group II) had not received. In any of the variables considered, age, sex, HBsAg, Child class, tumor number, tumor size, a- FP, operative method, no significant difference of patient characteristics between the two groups was found(p>0.05). Using the Kaplan-Meier Product-limit method and log-rank test, the differences of 1, 3, 5-year overall survival and disease-free survival rates, between these comparable groups were analyzed. The l, 3, 5-year overall survival rates in Group I and Group II were, respectively, 95.2%, 59.5%, 39.7% and 76.6%, 58.7%, 44.0%. Furthermore, the disease-free survival rates were, respectively, 81.5%, 50.3%, 50.3% and 69.4%, 43.9%, 30.8 %. This result indicates that there was no statistical significant difference between two groups in overall and disease-free survival. But, we gained a better results in Group I patients especially with total necrosis of tumor. So, further study, when & how we obtained total necrosis of hepatocellular carcinoma preoperatively, will be needed.

2,419 View
12 Download

First
Prev
Page of 1
Next
Last

Search